There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Panbela Therapeutics (PBLA – Research Report) and Assertio Therapeutics (ASRT – Research Report) with bullish sentiments.
Panbela Therapeutics (PBLA)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Panbela Therapeutics today and set a price target of $16.00. The company’s shares closed last Friday at $2.17, close to its 52-week low of $1.80.
According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Panbela Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.
See Insiders’ Hot Stocks on TipRanks >>
Assertio Therapeutics (ASRT)
In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Assertio Therapeutics, with a price target of $9.00. The company’s shares closed last Friday at $5.35.
According to TipRanks.com, Flaten is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Assertio Therapeutics with a $9.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PBLA:
- Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
- Panbela (NASDAQ:PBLA) Soars on $9.5M Asset Divestment to US WorldMeds
- Panbela Therapeutics to receive up to $9.5M for divestiture of assets
- Panbela Therapeutics issued new patent in Australia
- Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
